Navigation Links
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
Date:12/6/2007

o continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT:

Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...   Aratana Therapeutics, Inc . (NASDAQ: ... licensing, development and commercialization of innovative biopharmaceutical products for ... the Barclays Global Healthcare Conference to be ... Hotel in Miami , FL.  ... and Chief Executive Officer of Aratana Therapeutics, will provide ...
(Date:3/4/2015)... 2015  Results of the recent study, Results ... for Intra-Operative Positive Margin Detection , were presented as ... nd Annual Miami Breast Cancer Conference last week. ... Papa , MD, FACS, Professor of Surgery at the ... an analysis of MarginProbe,s efficiency and accuracy when used ...
(Date:3/4/2015)... 2015 Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in ... cancer, today announced that James A. Joyce , ... overview at the 27th Annual ROTH Conference on March ... Laguna Niguel, California . To learn more about ... A live webcast of the presentation will be ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2Aethlon Medical to Present at the 27th Annual ROTH Conference 2
... Plan for Biomarker Study -, MONTVALE, N.J., ... ) today announced that it plans to,conduct a ... nicotinic alpha-7,partial agonist, on two biomarkers of schizophrenia, ... schizophrenia. The biomarker study,and additional formulation and manufacturing ...
... Developed Test in the U.S. for Detecting the ... Mosquito-Borne Infectious Disease, ... diagnostics company of Quest Diagnostics (NYSE: DGX ),today announced ... mosquito-borne chikungunya virus. Commercial availability of,the molecular polymerase chain reaction ...
Cached Medicine Technology:Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 2Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 3Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 4Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 2Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 3Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 4
(Date:3/4/2015)... March 05, 2015 The emergence ... landscape over the past decade. The pharmaceutical world ... drug delivery in the form of liposomes and ... drugs with more safety and efficiency. In ... perhaps rely greatly upon the enhanced permeability and ...
(Date:3/4/2015)... Las Vegas, NV (PRWEB) March 04, 2015 ... good as the fight that is the main event. For ... announced and that fight will be for the UFC Featherweight ... against the brash, often out-spoken native of Ireland, Conor “Notorious” ... the MGM Grand Garden Arena in Las Vegas, NV. , ...
(Date:3/4/2015)... Florida (PRWEB) March 04, 2015 Ultraman ... a 6.2 mile swim, 261.4 mile bike, and 52.4 ... a total time of 24:45:45. , "This race was ... to my wonderful team and sponsors for supporting me ... Ultraman Florida 2015 had a total of 40 select ...
(Date:3/4/2015)... Dr. Christopher Asandra, M.D., Founder and Chief Medical ... the FDA’s recent decision to issue a warning ... FDA’s conclusions are not supported by science, and that ... deficiency. , “The FDA appears to have developed a ... Dr. Asandra. “There is not nearly enough evidence to ...
(Date:3/4/2015)... TROY Healthcare Solutions will be introducing TROY Secure ... of security for prescriptions, in Houston, Texas on Wednesday, ... located at 6633 Travis Street from 7 AM to ... Healthcare Solutions will host a continental breakfast. Starting at ... each hour to introduce attendees to TROY Secure Print ...
Breaking Medicine News(10 mins):Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 3Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3
... National Football League (NFL) will give a $1 million ... Traumatic Encephalopathy (CSTE) at Boston University School of Medicine ... funds will be used to continue the Center,s ground-breaking ... in athletes, in particular football players. CSTE researchers have ...
... Minn. -- The growing number of Americans with cardiovascular ... of chest pain. In a study published in the ... reported that patients dismissed from the hospital with noncardiac ... highlight a need for more aggressive cardiovascular risk factor ...
... for inflammation , TUESDAY, April 20 (HealthDay News) -- ... have something to do with components of virgin olive ... study reports. , "These findings strengthen the relationship between ... most basic level of healthy effects derived from virgin ...
... ... , ... 20, 2010 -- As the debate around legalization intensifies from coast to coast, CNBC.com ... of business. "Marijuana & Money" thoroughly examines the current marketplace as well as ...
... ... $2500 so far in a weight loss challenge, benefiting City CURE’s Whiz Kids program. Dr. ... is to raise $3000. City CURE is a non-profit organization in Cincinnati whose goal is ... ...
... "I was ... her pancreatic cancer. But the Chicago woman refused to give up in her fight ... Hepatobiliary Diseases at Northwest Community Hospital in Arlington Heights, where the expertise of Dr. Malcolm ... ...
Cached Medicine News:Health News:NFL gives $1 million unrestricted gift to Boston University to study impact of brain injuries 2Health News:NFL gives $1 million unrestricted gift to Boston University to study impact of brain injuries 3Health News:Outcomes of patients dismissed from the hospital with non-cardiac chest pain 2Health News:CNBC.com Presents "Marijuana & Money" 2Health News:CNBC.com Presents "Marijuana & Money" 3Health News:CNBC.com Presents "Marijuana & Money" 4Health News:Dr. Sachin Patel Partners with City CURE to Raise $3000 in a Pound-4-Pound Challenge Benefiting Whiz Kids 2Health News:Given No Chance to Survive with Pancreatic Cancer, Chicago Woman Finds New Life at Northwest Community Hospital 2Health News:Given No Chance to Survive with Pancreatic Cancer, Chicago Woman Finds New Life at Northwest Community Hospital 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: